Market Overview

Global Nonalcoholic Steatohepatitis (NASH) Therapeutics & Diagnostics Market Forecast to 2023: CAGR to Grow at 25% - ResearchAndMarkets.com

Share:

The "Global
Nonalcoholic Steatohepatitis Therapeutics and Diagnostics Market -
Segmented by Pipeline Therapeutics, Diagnostic Techniques, Treatment
Therapies, and Geography - Growth, Trends, and Forecast (2018 - 2023)"

report has been added to ResearchAndMarkets.com's
offering.

The global nonalcoholic steatohepatitis (NASH) therapeutics and
diagnostics market is expected to register a CAGR of 25% during the
forecast period of 2018-2023.

Rising Prevalence of Diabetic & Obese Population Globally

The increasing global prevalence of diabetic and obese population
particularly in the developed markets is expected to raise the NASH
therapeutics and diagnostics market. An estimated 5-20% of the
population accounting for nearly 15 million, shows the prevalence of
NASH consuming fatty acids diet in the United States, which is driven by
obesity and diabetes.

In the United Kingdom, as per the Diabetes Community, 2015, over four
million people were diagnosed with diabetes which represented 6% of the
United Kingdom's population, i.e., one in every 16. With that, the
United Kingdom had the fifth highest rate of obesity in Europe in 2015,
with nearly 25% of the population having body mass index of 30 or more.
A similar trend or higher could be found in several developed countries,
which raises the demand for NASH therapeutics and diagnostics market.

Other factors driving this market are the lucrative pipeline for NASH
therapeutics and emergence of novel biomarkers and improvement in liver
biopsy technologies.

Other Key Highlights

  • Slow Advances in the Therapeutic Field & the Lack of Effective
    Diagnostics for NAFLD
  • North America to Dominate the Market

Notable Developments in the Market

  • AstraZeneca licensed IONIS-AZ6-2.5-LRx, NASH drug from Ionis
    Pharmaceuticals, Inc. for USD 30 million.
  • NorthSea Therapeutics B.V. completed a EUR 25 million Series A funding
    for the development of icosabutate, an oral promising drug candidate
    for the treatment of NASH.

Companies Profiled

  • AstraZeneca PLC
  • Conatus Pharmaceuticals Inc.
  • Enzo Biochem Inc.
  • Galmed Pharmaceuticals Ltd.
  • Genfit Corp.
  • Gilead
  • Horizon Pharma PLC
  • Immuron
  • Intercept Pharmaceuticals Inc.
  • Novo Nordisk A/S

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Market Dynamics

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/qxzc3p/global?w=4

View Comments and Join the Discussion!